The findings of in vitro and in vivo anticancer studies using human colon cancer HCT116 cells confirmed that TRAIL-Cur-NPs showed an enhanced antitumor ability because of high tumor targeting and synergistic effect of TRAIL and Cur. The gene discussed is TNFSF10; the disease is colonic neoplasm.